A number of companies are in focus in Thursday trade with developments ranging from capital infusions and block deals to mergers and acquisitions. From Tata Steel and Akzo Nobel India to Glenmark Pharma, here are the key stocks to keep an eye on today.
Market recap
Indian equity benchmarks ended lower on September 24. The Nifty 50 slipped 113 points, or 0.45%, to close at 25,057, while the Sensex dropped 387 points, or 0.47%, finishing the day at 81,715.63.
Stocks to watch on September 25, 2025
Tata Steel
Tata Steel has injected fresh capital into T Steel Holdings(TSHP). The company subscribed to 457.7 crore equity shares worth Rs 4,054.66 crore. Each share has a face value of USD 0.1005. This takes Tata Steel’s total investment in TSHP for 2025 to $460 million.
Waaree Energies
Waaree Energies has infused Rs 300 crore into its subsidiary Waaree Energy Storage Solutions (WESSPL) through a rights issue. The funding was done by issuing 60 crore partly paid-up equity shares at Rs 10 each. Out of this, Rs 5 per share has been paid upfront, while the remaining Rs 5 will be collected later when called.
Akzo Nobel India
Akzo Nobel India, known for Dulux paints, saw a significant block deal on Wednesday. Promoter Imperial Chemical Industries sold 5% of the company’s stake. The transaction was valued at Rs 765 crore. Shares changed hands at an average of Rs 3,358.8 each. Institutional investors were active buyers. Nippon India picked up 1.8% for Rs 274 crore. WF Asian Smaller Companies Fund acquired 1.2% for Rs 174 crore. Other buyers included Goldman Sachs Funds, Baroda BNP Paribas Mutual Fund, and Aditya Birla Sun Life Mutual Fund.
Glenmark Pharma
Glenmark Pharmaceuticals subsidiary, Glenmark Specialty S.A., entered an exclusive license and collaboration agreement with Hengrui Pharma. The partnership focuses on Trastuzumab Rezetecan (SHR-A1811), a next-generation HER2-targeting antibody drug conjugate. Glenmark will make an upfront payment of $18 million. Hengrui may receive milestone payments up to $1.093 billion. Glenmark will also pay royalties based on net sales in the licensed territory.
Ipca Laboratories
Ipca Laboratories entered a partnership with BioSimilar Sciences PR LLC (BSS), USA. The collaboration focuses on a next-generation monoclonal antibody biosimilar targeting cancer and autoimmune diseases. Ipca will transfer late-stage development, clinical manufacturing, and commercial supply to BSS’ 200,000 sq. ft facility in Puerto Rico.
Poly Medicure
Medical device company Poly Medicure has signed an agreement to acquire Medistream SA. This includes Citieffe SRL and its subsidiaries in the US and Mexico. The deal is valued at Rs 324 crore.
Piramal Enterprises
The National Company Law Tribunal (NCLT) approved the merger of Piramal Enterprises with its subsidiary Piramal Finance. After the merger, Anand Piramal will chair Piramal Finance. Ajay Piramal will continue to lead the Piramal Group. Vice-chair Swati Piramal retains her role.
Birla Corp
RCCPL Private, a subsidiary of Birla Corporation, has won the bid for the Kanpa-Junapani limestone block in Adilabad, Telangana. The final bid was 87.05% of the base price. The block covers 3.38 sq km.
Dalmia Bharat
Dalmia Bharat received confirmation of a provisional land attachment from the Adjudicating Authority under the Prevention of Money Laundering Act (PMLA). The land is valued at Rs 377.26 crore. This confirms a previous attachment order of Rs 793.34 crore issued by the Enforcement Directorate in March 2025.